CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

carmustine

Trade name: bicnu

Small moleculeapproved

Approved

Jun 1, 1962

Carmustine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Carmustine is used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross-resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. Pulmonary toxicity characterized by pulmonary infiltrates and/or fibrosis has been reported to occur from 9 days to 43 months after treatment with BiCNU and related nitrosoureas. A frequent and serious toxicity of BiCNU is delayed myelosuppression. Nausea and vomiting after intravenous administration of BiCNU are noted frequently. Greater myelotoxicity (e.g., leukopenia and neutropenia) has been reported when carmustine was combined with cimetidine. — NCATS

Clinical trial activity

219 trials · 166 clinical orgs · 20 marketing orgs

Phase 1
52
Phase 2
177
Phase 3
42
Phase 4
0

Earliest trial started Apr 1, 1988 (NCT00002461)

Timeline

1960s

  1. Jun 1, 1962

    Earliest FDA Approval

1970s

  1. Mar 7, 1977

    Bristol-Myers — First NDA Organization

  2. Mar 7, 1977

    Bristol-Myers — NDA Organization

  3. Mar 7, 1977

    Emcure — NDA Secondary Org

  4. Mar 7, 1977

    Avet Lifesciences — Marketing Organization

  5. Mar 7, 1977

    Avet Lifesciences — NDA Secondary Org

1980s

  1. Jan 1, 1988

    Earliest Phase 2 Sponsor(trial)

1990s

  1. Jan 1, 1990

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1995

    Earliest Phase 1 Sponsor(trial)

  3. Sep 23, 1996

    Arbor Pharmaceuticals — NDA Secondary Org

  4. Sep 23, 1996

    Azurity — Marketing Organization

  5. Sep 23, 1996

    Azurity — NDA Secondary Org

2010s

  1. Sep 11, 2018

    Navinta — Marketing Organization

  2. Oct 16, 2018

    Amneal Pharmaceuticals — Marketing Organization

  3. Apr 2, 2019

    STI Pharma, LLC — Marketing Organization

  4. Apr 2, 2019

    PENN LIFE — Marketing Organization

2020s

  1. Oct 22, 2020

    Dr. Reddy's Laboratories — Marketing Organization

  2. Mar 12, 2021

    Hengrui Therapeutics, Inc. — Marketing Organization

  3. Mar 12, 2021

    Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — Marketing Organization

  4. Aug 2, 2021

    Meitheal — Marketing Organization

  5. May 16, 2022

    Accord Research — Marketing Organization

  6. May 16, 2022

    Accord Research — NDA Secondary Org

  7. Jun 21, 2022

    Ingenus Pharmaceuticals — Marketing Organization

  8. Jun 21, 2022

    Novast Labs — Marketing Organization

  9. Mar 3, 2023

    Mylan — Marketing Organization

  10. Mar 3, 2023

    PHARMOBEDIENT — Marketing Organization

  11. May 11, 2023

    MSN Laboratories — Marketing Organization

  12. Oct 20, 2023

    Alembic — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 1, 1962

Chemistry & pharmacology

Loading structure…

SMILES

ClCCNC(=O)N(CCCl)N=O
Mol. weight
214.05 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • bcnu
  • bcnu
  • bcnu
  • bcnu
  • becenun
  • bicnu
  • bicnu
  • bicnu
  • bicnu (tn)
  • bicnu (tn)
  • bis-chloroethylnitrosourea
  • bischloroethyl nitrosourea
  • bischloroethyl nitrosourea
  • carmubris
  • carmustin
  • carmustina
  • carmustina
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine
  • carmustine - poliferprosan
  • carmustine, poliferprosan 20 drug combination
  • carmustinum
  • carmustinum
  • gliadel
  • gliadel
  • gliadel
  • gliadel
  • nitrumon
  • n,n'-bis(2-chloroethyl)-n-nitrosourea
  • n,n'-bis(2-chloroethyl)-n-nitrosourea

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07199296Phase 2Jul 1, 2025Anhui Medical University, Central South University, Fudan University, Fujian Medical University, Jiao Tong University, Shandong University, Wenzhou Medical University
NCT06692452Phase 2Apr 30, 2025Harvard University, Ipsen
NCT06687772Phase 2Feb 28, 2025Washington University in St. Louis
NCT06377540Phase 2Dec 1, 2024University of Minnesota
NCT06652139Phase 2Nov 1, 2024Jiao Tong University
NCT06626516Phase 1/Phase 2 (Phase 2)Oct 31, 2024Thomas Jefferson University
NCT05863845N/AJun 1, 2023Jiao Tong University
NCT05931263Phase 3Jun 1, 2023Nanjing Medical University
NCT05521984Phase 1Jan 31, 2023Washington University in St. Louis
NCT05228249Phase 1Dec 7, 2022ADC Therapeutics SARL, University of Washington
NCT05466318Phase 3Jul 1, 2022Sichuan University
NCT04871607Phase 2Nov 1, 2021City of Hope National Medical Center, National Cancer Institute (NCI)
NCT05052957Phase 2Oct 15, 2021Case Western Reserve University, National Cancer Institute (NCI)
NCT04728633Phase 2Sep 27, 2021Thomas Jefferson University
NCT04582604Phase 1/Phase 2 (Phase 2)Sep 1, 2020People's Liberation Army of China
NCT04150042Phase 2Mar 31, 2020General Oncology, Inc.
NCT04222062Phase 2Feb 1, 2020Arbor Pharmaceuticals, University of Nebraska
NCT03736616Phase 2Nov 30, 2018Acerta Pharma, University of Washington
NCT03591861Phase 1Sep 30, 2018Washington University in St. Louis
NCT03579927Phase 1/Phase 2 (Phase 2)Sep 21, 2018National Cancer Institute (NCI), University of Texas at Houston
Showing 20 of 219 trials
Page 1 / 11

Organizations

Research & Development (166)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government1002141993
Cornell UniversityAcademic/Hospital141341990
University of Texas at HoustonAcademic/Hospital141231995
University of WashingtonAcademic/Hospital141241999
Duke UniversityAcademic/Hospital111121997
City of Hope National Medical CenterAcademic/Hospital10941998
Case Western Reserve UniversityAcademic/Hospital8621996
University of MarylandAcademic/Hospital8811998
Eastern Cooperative Oncology GroupAcademic/Hospital7111994
Johns Hopkins UniversityAcademic/Hospital7131996
Southwest Oncology GroupAcademic/Hospital7721994
University of MinnesotaAcademic/Hospital7622000
University of NebraskaAcademic/Hospital7611995
Washington University in St. LouisAcademic/Hospital7621998
EisaiFor profit6112002
Mayo ClinicAcademic/Hospital6021994
Stanford UniversityAcademic/Hospital6532000
Cancer and Leukemia Group B (CALGB)Academic/Hospital5011994
European Organisation for Research and Treatment of CancerAcademic/Hospital5321994
GenentechFor profit5012000
166 organizations
Page 1 / 9

Marketing (25)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGMay 16, 2022
Accord ResearchFor profitNDA2May 16, 2022
AlembicFor profitMKTGOct 20, 2023
Amneal PharmaceuticalsFor profitMKTGOct 16, 2018
Amneal PharmaceuticalsFor profitSYNOct 16, 2018
Arbor PharmaceuticalsFor profitNDA2Sep 23, 1996
Avet LifesciencesFor profitMKTGMar 7, 1977
Avet LifesciencesFor profitNDA2Mar 7, 1977
AzurityFor profitMKTGSep 23, 1996
AzurityFor profitNDA2Sep 23, 1996
Bristol-MyersFor profitNDAMar 7, 1977
Dr. Reddy's LaboratoriesFor profitMKTGOct 22, 2020
EmcureFor profitNDA2Mar 7, 1977
Hengrui Therapeutics, Inc.For profitMKTGMar 12, 2021
Hengrui Therapeutics, Inc.For profitSYNMar 12, 2021
Ingenus PharmaceuticalsFor profitMKTGJun 21, 2022
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.For profitMKTGMar 12, 2021
MSN LaboratoriesFor profitMKTGMay 11, 2023
MeithealFor profitMKTGAug 2, 2021
MylanFor profitMKTGMar 3, 2023
NavintaFor profitMKTGSep 11, 2018
Novast LabsFor profitMKTGJun 21, 2022
PENN LIFEFor profitMKTGApr 2, 2019
PHARMOBEDIENTFor profitMKTGMar 3, 2023
STI Pharma, LLCFor profitMKTGApr 2, 2019